In the latest Cancer Matters podcast, Dr Bill Nelson speaks with Dr Patrick Forde about the results of a clinical trial that show pairing immunotherapy… Read More »Cancer Matters with Dr. Bill Nelson – The Checkmate 816 Trial
Dr Akila Viswanathan talks with Dr Wilfred Ngwa about both his work as the Director of the Global Health Catalyst, which aims to reduce cancer… Read More »On Target with Dr. Akila Viswanathan – Global Health Catalyst
In the latest Cancer Matters podcast, Dr Bill Nelson talks with Dr Janis Taube and Dr Alex Szalay about AstroPath, a new platform that combines… Read More »Cancer Matters with Dr. Bill Nelson – AstroPath
Arnold’s advanced pancreas cancer that had spread to his liver was eliminated with a low-dose, five-drug combination being studied in a clinical trial led by… Read More »New Advances in Therapies: Five-Drug Combo
Researchers at the Johns Hopkins Kimmel Cancer Center are studying the immune system to find what does and doesn't work to better fight soft tissue… Read More »Immune Cells Hampered When Fighting Soft Tissue and Bone Sarcomas
Clement Okoh is a cancer survivor, author, entrepreneur….and proud grandfather. Cancer Matters is sharing book excerpts of his personal journey, “OSONDU,", an inspiring story of… Read More »OSONDU: The Race for Life (Part 3)
In this Cancer Matters podcast, Dr Bill Nelson talks with Dr Julie Brahmer about the advances made in treating patients with lung cancer, smoking cessation… Read More »Cancer Matters with Dr. Bill Nelson – Advances in Lung Cancer
In the next On Target podcast, Dr Akila Viswanathan speaks with Dr Lawrence Kleinberg about the treatment of brain cancer and engaging the immune system… Read More »On Target with Dr. Akila Viswanathan – Brain Cancer
Janice Paulshock is a busy woman. The 58-year-old resident of Harford County, a Maryland suburb, works full-time; is a committed mother and grandmother; runs to… Read More »Meet Janice Paulshock: Twenty-Year Advanced Stage Ovarian Cancer Survivor
Combinations strategies involving checkpoint immunotherapies were approved as first-line options in two cancer types and showed promise in clinical trials for several hard-to-treat cancers. Important… Read More »Jaffee looks to the future of checkpoint immunotherapy for cancer treatment